Development and internal validation of an NT-proBNP/NPR-based model for predicting 3-month early mortality in advanced light-chain cardiac amyloidosis

Patients with advanced light-chain cardiac amyloidosis (AL-CA) remain at high risk of early death despite therapeutic progress. Prognostic heterogeneity within Mayo 2012 stage III/IV disease limits identification of ultra-high-risk patients during initial treatment. We retrospectively included 111 patients with Mayo 2012 stage III/IV AL-CA and randomly divided them into training and internal validation cohorts at a 2:1 ratio. The primary endpoint was all-cause mortality within 3 months after diagnosis. In the training cohort ( n = 74), 24 patients died within 1 year, including 16 deaths within 3 months. Kaplan-Meier analysis showed a biphasic survival pattern with a sharp early decline followed by plateauing. Univariate and multivariable Cox analyses identified NT-proBNP and neutrophil-to-platelet ratio (NPR) as prognostically relevant variables for 3-month mortality. Both remained significantly associated with early mortality after additional adjustment for daratumumab-based frontline therapy. Using receiver operating characteristic (ROC)-derived cutoffs, we developed a simple model based on NT-proBNP > 5906 ng/L and NPR > 4.015. Patients meeting both criteria were classified as high-risk. The model stratified 3-month survival in the training cohort (area under the curve, AUC = 0.724, 95% CI 0.604–0.858) and retained discrimination in the validation cohort ( n = 37, AUC = 0.653, 95% CI 0.483–0.841). A complementary continuous NT-proBNP/NPR model yielded AUCs of 0.730 and 0.759 in the training and validation cohorts, respectively. Bootstrap internal validation of the continuous model using the entire cohort yielded an optimism-corrected C-index of 0.704 and an optimism-corrected calibration slope of 0.830. These findings support a simple NT-proBNP/NPR-based model for early mortality risk stratification in patients with advanced AL-CA, and may help identify ultra-high-risk patients and guide risk-adapted clinical decision-making.

Authors

Institutions

Publication Details

Journal
BMC Cardiovascular Disorders
Published
2026-11-17
DOI
https://doi.org/10.1186/s12872-026-07029-4
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development and internal validation of an NT-proBNP/NPR-based model for predicting 3-month early mortality in advanced light-chain cardiac amyloidosis

Yue Song, Chen Gong, Tiankuo Gao, Xinyang Zhang et al.
3 links
BMC Cardiovascular Disorders
Amyloidosis: Diagnosis, Treatment, Outcomes
article

Development and internal validation of an NT-proBNP/NPR-based model for predicting 3-month early mortality in advanced light-chain cardiac amyloidosis

Yue Song, Chen Gong, Tiankuo Gao, Xinyang Zhang, Yingxin Zhu, Yini Wang, Chun Yang, Jinglin Hu
article en

Abstract

Patients with advanced light-chain cardiac amyloidosis (AL-CA) remain at high risk of early death despite therapeutic progress. Prognostic heterogeneity within Mayo 2012 stage III/IV disease limits identification of ultra-high-risk patients during initial treatment. We retrospectively included 111 patients with Mayo 2012 stage III/IV AL-CA and randomly divided them into training and internal validation cohorts at a 2:1 ratio. The primary endpoint was all-cause mortality within 3 months after diagnosis. In the training cohort ( n = 74), 24 patients died within 1 year, including 16 deaths within 3 months. Kaplan-Meier analysis showed a biphasic survival pattern with a sharp early decline followed by plateauing. Univariate and multivariable Cox analyses identified NT-proBNP and neutrophil-to-platelet ratio (NPR) as prognostically relevant variables for 3-month mortality. Both remained significantly associated with early mortality after additional adjustment for daratumumab-based frontline therapy. Using receiver operating characteristic (ROC)-derived cutoffs, we developed a simple model based on NT-proBNP > 5906 ng/L and NPR > 4.015. Patients meeting both criteria were classified as high-risk. The model stratified 3-month survival in the training cohort (area under the curve, AUC = 0.724, 95% CI 0.604–0.858) and retained discrimination in the validation cohort ( n = 37, AUC = 0.653, 95% CI 0.483–0.841). A complementary continuous NT-proBNP/NPR model yielded AUCs of 0.730 and 0.759 in the training and validation cohorts, respectively. Bootstrap internal validation of the continuous model using the entire cohort yielded an optimism-corrected C-index of 0.704 and an optimism-corrected calibration slope of 0.830. These findings support a simple NT-proBNP/NPR-based model for early mortality risk stratification in patients with advanced AL-CA, and may help identify ultra-high-risk patients and guide risk-adapted clinical decision-making.

BMC Cardiovascular Disorders
Capital Medical University (CN), Beijing Anzhen Hospital (CN)
Good health and well-being
Amyloidosis: Diagnosis, Treatment, Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon